Details of the Drug Combinations

General Information of This Drug (ID: DM8S6T7)

Drug Name
Ivosidenib   DM8S6T7
Synonyms
UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1]
Cholangiocarcinoma 2C12.10 Phase 3 [2]
Haematological malignancy 2B33.Y Phase 1 [3]
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Ivosidenib + Marizomib DCBA06T Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
------------------------------------------------------------------------------------
5 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Fedratinib + Ivosidenib DC3LHZK Fedratinib IDH Mutation [5]
Ivosidenib + Gilteritinib DCMA1UH Gilteritinib Acute Myeloid Leukemia (AML) [6]
Venetoclax + Ivosidenib DCGGTZ7 Venetoclax Acute Myeloid Leukemia [7]
Enasidenib + Ivosidenib DCOY10X Enasidenib Acute Myeloid Leukemia [8]
Ivosidenib + Azacitidine DCDNOQ3 Azacitidine Newly Diagnosed Acute Myeloid Leukemia (AML) [9]
------------------------------------------------------------------------------------

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 ClinicalTrials.gov (NCT02989857) Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02073994) Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation. U.S. National Institutes of Health.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 ClinicalTrials.gov (NCT04955938) A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
6 ClinicalTrials.gov (NCT05756777) A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
7 ClinicalTrials.gov (NCT03471260) Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
8 ClinicalTrials.gov (NCT03839771) A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
9 ClinicalTrials.gov (NCT03173248) Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation